TY - JOUR
T1 - Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone
T2 - A retrospective study
AU - Quattrini, Irene
AU - Pollino, Serena
AU - Pazzaglia, Laura
AU - Conti, Amalia
AU - Novello, Chiara
AU - Ferrari, Cristina
AU - Pignotti, Elettra
AU - Picci, Piero
AU - Benassi, Maria Serena
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Giant cell tumor of bone (GCTb) represents 5% of bone tumors, and although considered benign, 5% metastasize to the lung. The expression of proteins directly or indirectly associated with osteolysis and tumor growth was studied on 163 samples of GCTb. Of these, 33 patients developed lung metastasis during follow-up. The impact of tumor-host interaction on clinical aspects was evaluated with the aim of finding specific markers for new biological therapies, thus improving clinical management of GCTb. Protein expression was evaluated by immunohistochemical analysis on Tissue Microarray. The majority of GCTb samples from patients with metastatic disease were strongly positive to RANKL and its receptor RANK as well as to CAII and MMP-2 and to pro-survival proteins NFIB and c-Fos. Kaplan-Meier analysis indicated a significant difference in metastasis free survival curves based on protein staining. Interestingly, the statistical correlation established a strong association between all variables studied with a higher τ coefficient for RANK/RANKL, RANK/NFIB, and RANKL/NFIB pairs. At multivariate analysis co-overexpression of NFIB, RANK and RANKL significantly increased the risk of metastasis with an odds ratio of 13.59 (95%CI 4.12-44.82; p
AB - Giant cell tumor of bone (GCTb) represents 5% of bone tumors, and although considered benign, 5% metastasize to the lung. The expression of proteins directly or indirectly associated with osteolysis and tumor growth was studied on 163 samples of GCTb. Of these, 33 patients developed lung metastasis during follow-up. The impact of tumor-host interaction on clinical aspects was evaluated with the aim of finding specific markers for new biological therapies, thus improving clinical management of GCTb. Protein expression was evaluated by immunohistochemical analysis on Tissue Microarray. The majority of GCTb samples from patients with metastatic disease were strongly positive to RANKL and its receptor RANK as well as to CAII and MMP-2 and to pro-survival proteins NFIB and c-Fos. Kaplan-Meier analysis indicated a significant difference in metastasis free survival curves based on protein staining. Interestingly, the statistical correlation established a strong association between all variables studied with a higher τ coefficient for RANK/RANKL, RANK/NFIB, and RANKL/NFIB pairs. At multivariate analysis co-overexpression of NFIB, RANK and RANKL significantly increased the risk of metastasis with an odds ratio of 13.59 (95%CI 4.12-44.82; p
KW - bone remodeling
KW - giant cell tumor
KW - metastasis
KW - prognostic biomarkers
UR - http://www.scopus.com/inward/record.url?scp=84936847442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936847442&partnerID=8YFLogxK
U2 - 10.1002/jor.22873
DO - 10.1002/jor.22873
M3 - Article
C2 - 25764026
AN - SCOPUS:84936847442
SN - 0736-0266
VL - 33
SP - 1205
EP - 1211
JO - Journal of Orthopaedic Research
JF - Journal of Orthopaedic Research
IS - 8
ER -